

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **TERADA, Hiroshi, et al.**

Group Art Unit: **1618**

Serial No.: **10/525,964**

Examiner: **HARTLEY, Michael G.**

Filed: **October 13, 2005**

P.T.O. Confirmation No.: 3134

For: **REMEDY**

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

October 4, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.



The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS,

HANSON & BROOKS, LLP

*James E. Armstrong, IV*  
James E. Armstrong, IV

Attorney for Applicants

Reg. No. 42,266

JAM/rk

Atty. Docket No. **050106**

Suite 1000

1725 K Street, N.W.

Washington, D.C. 20006


(202) 659-2930



**23850**

PATENT TRADEMARK OFFICE

Enclosures: PTO-1449 and references (6)



<b>INFORMATION DISCLOSURE CITATION PTO-1449</b>	Atty. Docket No. <b>050106</b>	Serial No. <b>10/525,964</b>
	Applicant(s): <b>TERADA, Hiroshi, et al.</b>	
	Filing Date: <b>October 13, 2005</b>	Group Art Unit: <b>1618</b>

### U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	AA					
_____	AB					

### FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____	AC		
_____	AD		

### OTHER DOCUMENTS

_____	AE	TAKAHASHI, K. et al. "Life-Supporting Macrophages;" <i>Bunkodo</i> ; pp.141-146 (2001); and English translation.
_____	AF	SUAREZ, S., et al. "Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in an Infectious Disease Model;" <i>Pharmaceutical Research</i> ; Vol.18, No.9, pp.1315-1319 (2001), and cover sheets (2 sheets).
_____	AG	PRIOR, S., et al. "In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres;" <i>European Journal of Pharmaceutical Sciences</i> ; Vol.15, pp.197-207 (2002), and cover sheets (2 sheets).
_____	AH	MATSUYAMA, T., et al. "Cytocidal Effect of Tumor Necrosis Factor on Cells Chronically Infected with Human Immunodeficiency Virus (HIV): Enhancement of HIV Replication;" <i>JOURNAL OF VIROLOGY</i> ; Vol.63, No.6, pp.2504-2509 (1989).
_____	AI	PUSHKARSKY, T., et al. "Lipopolysaccharide stimulates HIV-1 entry and degradation in human macrophages;" <i>Journal of Endotoxin Research</i> ; Vol.7, No.4, pp.271-276 (2001).
_____	AJ	MATSUMOTO, N., et al. "ONO-4007, an Antitumor Lipid A Analog, Induces Tumor Necrosis Factor- $\alpha$ Production by Human Monocytes Only under Primed State: Different Effects of ONO-4007 and Lipopolysaccharide on Cytokine Production;" <i>THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS</i> ; Vol.284, No.1, pp.189-195 (1998).
Examiner	/Paul Dickinson/	
Date Considered	02/27/2008	